Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance  COVID-19 status Phase of research How it helps Latest publication
A-2F1
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
A-2H4
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
Abacavir
Potential treatment - theoretical effect Used to treat other disease Antiviral Feb/22/2020
Abametapir
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
ABBV-744
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020
Abemaciclib
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Sep/21/2020
Abiraterone acetate
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jul/13/2020
ABP-700
Potential treatment - theoretical effect Experimental Antiviral Nov/06/2020
ABP18
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
AC-55541
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020
Ac-QS5-VS
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/22/2020
AC1MTT7T
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/26/2020
Acarbose
Potential treatment - theoretical effect Used to treat other disease Antiviral Nov/12/2020
ACE2 1–618-ABD
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021
ACE2 microbody
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/01/2020
ACE2 receptor trap
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/22/2020
ACE2-GpA-RBC
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/10/2021
ACE2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020
ACE2‐Fc
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/26/2022
ACE2‐TMPRSS2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020